-
admin
Posts
Corn Next Launches CornNext-17: A Groundbreaking Sustainable Solution to Plastic Pollution
IRVINE, Calif., Jan. 11, 2025 /PRNewswire/ — Corn Next, a leader in sustainable innovation and biodegradable solutions, has officially launched CornNext-17, a game-changing bio-based material...
Boqii Announces ADS Ratio Change
SHANGHAI, Jan. 11, 2025 /PRNewswire/ — Boqii Holding Limited (“Boqii” or the “Company”) (NYSE American: BQ) today announced that it will change its ratio of its...
UGREEN Unveils Groundbreaking AI NAS with Built-In LLM at CES 2025
LAS VEGAS, Jan. 11, 2025 /PRNewswire/ — UGREEN, a leading innovator in consumer electronics, made waves at CES 2025 with the unveiling of pioneering AI...
Regor Releases Phase 2a Topline Results for RGT-075, an Oral Once-daily Small Molecule GLP-1R Agonist, and Begins Phase 2b Study in the US for the Treatment of Obesity
Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral GLP-1RA, reporting 5% placebo-adjusted weight-loss with no plateau No treatment-related severe...
Liquid Youth Nutrition and Wildside Online Partner to Promote the 19th Annual Liquid Youth 13.1 Fort Lauderdale Running Festival on November 9, 2025. Register Now!
FORT LAUDERDALE, FL, Jan. 10, 2025 (GLOBE NEWSWIRE) — Liquid Youth Nutrition, a leader in premium collagen beverage products, and Wildside Online Inc., a globally...
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC
New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart) against XEC Centers for Disease Control reports XEC and KP.3.1.1 (previously disclosed as...
Tilray Brands Reports Q2 2025 Financial Results
Gross Profit Increased by 29% Year-Over-Year, Reaching $61 Million in Q2 with Growth Across All Four Business Segments Achieved 9% Year-Over-Year Growth, Generating Record Q2...
Belharra Therapeutics Announces Appointment of Sean Buchanan, Ph.D., as Chief Scientific Officer and Retirement of Gary O’Neill, Ph.D.
Dr. Buchanan will helm Belharra’s research organization as the company progresses its lead immunology and oncology programs, advances activities with its pharma collaborators, and enriches...
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
—ORLADEYO net revenue expected to be between $515-$535 million in 2025— —Total revenue (including RAPIVAB®) expected to be between $540-$560 million in 2025— —Company achieved...
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
– Vepdegestrant to be combined with Pfizer’s novel investigational CDK4 inhibitor atirmociclib in a first-line Phase 3 trial planned to initiate in 2025; a second-line...
